hyperlipidemias

The VICTORION-PLAQUE trial in primary prevention evaluates inclisiran, a small interfering RNA targeting PCSK9, for effects on atherosclerotic plaque using prespecified multimodality imaging endpoints. Randomized and double-blind, with dosing at day 1, day ...